NasVax develops innovative biopharmaceutical products improving the effectiveness or administration of vaccines. The Company applies its platform technology to create adjuvant agents, which enhance the response of the body's immune system to vaccines, and produces needle-free, intranasal vaccine delivery vehicles.

The Company's proprietary platform technology was developed by its co-founder, Prof. Yechezkel Barenholz along with Prof. Eli Kedar from the Hadassah Medical School of the Hebrew University of Jerusalem, in collaboration with Bio-Lab Ltd., Jerusalem. Prof. Barenholz is the co-inventor of Doxil^TM, a liposomal formulation of doxorubicin for cancer treatment, marketed in the USA by Johnson & Johnson and in Europe by Schering Plough (as Caelyx). NasVax's novel technology is protected by several registered patents and patent applications worldwide.

In the short time since its inception, based on the results of intensive studies conducted by the Barenholz/Kedar research teams, the Company advanced its intranasal delivery system for influenza vaccine from bench to clinical trials, in less than 18 months. Within one year of operations, the Company completed two private investment rounds; the second round was made by Pontifax venture capital fund, founded in 2004 by Eli Hurvitz, Chairman and former CEO of Teva Pharmaceutical Industries. Following a successful IPO on December 2005, it turned into a public company traded on the Tel Aviv Stock Exchange (TASE).